Clinical trial
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell…
NCT03474965 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03474965 |
|---|---|
| Title | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients |
| Official title | A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease (SCD) |
| Intervention type | Drug |
| Interventions | Crizanlizumab |
| Enrollment | 117 |
| Start date | Oct 1, 2018 |
| Primary completion | Nov 6, 2024 |
| Completion | Nov 6, 2024 |
| First posted | Mar 23, 2018 |
| Last update posted | Oct 16, 2025 |
| Countries | Belgium, Brazil, Canada, Colombia, France, Germany, India, Italy, Lebanon, Oman, Spain, Turkey (Türkiye) and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: